Acurx Pharmaceuticals LLC (ACXP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Acurx Pharmaceuticals LLC (ACXP) has a cash flow conversion efficiency ratio of -0.210x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.71 Million) by net assets ($8.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Acurx Pharmaceuticals LLC stock valuation for the company's overall valuation and market capitalisation.
Acurx Pharmaceuticals LLC - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Acurx Pharmaceuticals LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Acurx Pharmaceuticals LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acurx Pharmaceuticals LLC ranked by their cash flow conversion efficiency. See Acurx Pharmaceuticals LLC (ACXP) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Megado Minerals Ltd
AU:MEG
|
-0.069x |
|
HYDROTOR SA
WAR:HDR
|
0.017x |
|
Iron Road Ltd
AU:IRD
|
-0.021x |
|
Trinex Minerals Ltd
AU:TX3
|
-0.213x |
|
SKK Holdings Limited
NASDAQ:SKK
|
-0.003x |
|
Wa Kaolin Ltd
AU:WAK
|
-0.953x |
|
enVVeno Medical Corp
NASDAQ:NVNO
|
-0.149x |
|
Westbond Enterprises Corp
V:WBE
|
0.025x |
Annual Cash Flow Conversion Efficiency for Acurx Pharmaceuticals LLC (2019–2025)
The table below shows the annual cash flow conversion efficiency of Acurx Pharmaceuticals LLC from 2019 to 2025. View ACXP stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.27 Million | $-6.79 Million | -1.288x | +92.37% |
| 2024-12-31 | $615.12K | $-10.38 Million | -16.880x | -703.75% |
| 2023-12-31 | $4.67 Million | $-9.80 Million | -2.100x | -103.69% |
| 2022-12-31 | $7.32 Million | $-7.54 Million | -1.031x | -155.22% |
| 2021-12-31 | $12.41 Million | $-5.01 Million | -0.404x | +67.44% |
| 2020-12-31 | $2.70 Million | $-3.35 Million | -1.241x | +74.48% |
| 2019-12-31 | $819.85K | $-3.99 Million | -4.861x | -- |
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more